Huntingtons Disease Treatment Market: By Drug Class, By Route of Administration, By Distribution Channel and Region Forecast 2020-2031

download arrow download arrow Download Sample
settings arrow settings arrow email us

Huntingtons Disease Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Anticonvulsants, Antidepressants, Antidopaminergics, Antipsychotics, Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospitals pharmacies, Retail pharmacies, Online pharmacies) and Region Forecast 2020-2031

checked icon checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

Huntingtons Disease Treatment Market size was valued at US$ 202.6 million in 2024 and is expected to reach US$ 760.4 million by 2031, growing at a significant CAGR of 20.8% from 2025-2031. Huntingtons disease is an inherited disorder caused due to degeneration of the nerve cells in the brain. Huntingtons disease signs and symptoms appear in people with 30 to 40 years of age and sometimes disease causes in below 20 years of age group. Most common symptoms of Huntington's disease include difficulties in learning, lack of flexibility, muscle problems, abnormalities in speech, and lack of impulse control. Moreover, depression is the most common psychiatric disorder occurs with Huntington's disease and caused due to damage of brain cells and changes in brain function. There is no permanent treatment for Huntington's disease however, medications are available to manage the symptoms of Huntington's disease.

Key Developments

  • In April 2017, Teva Pharmaceuticals Industries Ltd. received U.S. FDA approval for Austedo tablets used in the treatment of Huntington's disease treatment. In September 2016, Voyager Therapeutics, Inc. collaborated with CHDI Foundation, Inc. (CHDI) foundation to develop novel gene therapy for the treatment of Huntington's disease.

summary download arrow Download Sample

Huntingtons Disease Treatment Market Summary

Study Period

2025-2031

Base Year

2024

CAGR

20.8%

Largest Market

North-America

Fastest Growing Market

Asia-Pacific

Huntingtons Disease Treatment Market Dynamics

Increase in the prevalence of Huntingtons disease, a rise in R&D activities for the innovation of newer drugs, availability of symptomatic treatment drugs, and rise in the geriatric population is anticipated to fuel the market over the forecast period.

Moreover, favourable reimbursement policies, a rise in the awareness regarding mental health among key stakeholders, and various pipeline drugs are driving the market growth. However, stringent regulatory guidelines and a dearth of treatment options are expected to hinder the growth of the market.

Huntingtons Disease Treatment Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2025-2031

Market Size in 2024

US$ 202.6 million

Market Size in 2031

US$ 760.4 million

Market CAGR

20.8%

By Drug Class

  • Anticonvulsants
  • Antidepressants
  • Antidopaminergics
  • Antipsychotics
  • Others

By Route-Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospitals pharmacies
  • Retail pharmacies
  • Online pharmacies

By Region

  • North America (U.S., Canada)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
  • Latin America (Mexico, Brazil, Argentina, Columbia, Rest of Latin America)
  • Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)

Key Features of the Report

  • The huntingtons disease treatment market report provides granular level information about the market size, regional market share, historic market (2020-2024), and forecast (2025-2031)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

Huntingtons disease treatment market size was valued at US$ 202.6 million in 2024 and is expected to reach US$ 760.4 million by 2031, growing at a significant CAGR of 20.8%.

The market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

The market key players are: Teva Pharmaceuticals Industries Ltd. (Israel), Valent Pharmaceuticals International Inc. (Canada), Alnylam Pharmaceuticals, Inc. (U.S.), Intellect Neurosciences, Inc. (U.S.), H. Lundbeck A/S (Denmark)

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1. Executive Summary
2. Global Huntingtons Disease Treatment Market Introduction 
2.1.Global Huntingtons Disease Treatment Market  - Taxonomy
2.2.Global Huntingtons Disease Treatment Market  - Definitions
2.2.1.Drug Class
2.2.2.Route of Administration
2.2.3.Distribution Channel
2.2.4.Region
3. Global Huntingtons Disease Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Huntingtons Disease Treatment Market Analysis, 2020-2024 and Forecast 2025-2031
4.1.  Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Huntingtons Disease Treatment Market  By Drug Class, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million)
5.1. Anticonvulsants
5.1.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Antidepressants
5.2.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Antidopaminergics
5.3.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Antipsychotics
5.4.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Others
5.5.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
6. Global Huntingtons Disease Treatment Market  By Route of Administration, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million)
6.1. Oral
6.1.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Parenteral
6.2.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
7. Global Huntingtons Disease Treatment Market  By Distribution Channel, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million)
7.1. Hospitals pharmacies
7.1.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail pharmacies
7.2.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Online pharmacies
7.3.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8. Global Huntingtons Disease Treatment Market  By Region, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9. North America Huntingtons Disease Treatment Market ,2020-2024 and Forecast 2025-2031 (Sales Value USD Million)
9.1. Drug Class Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Anticonvulsants
9.1.2.Antidepressants
9.1.3.Antidopaminergics
9.1.4.Antipsychotics
9.1.5.Others
9.2.  Route of Administration Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Oral
9.2.2.Parenteral
9.3.  Distribution Channel Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospitals pharmacies
9.3.2.Retail pharmacies
9.3.3.Online pharmacies
9.4.  Country Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10. Europe Huntingtons Disease Treatment Market ,2020-2024 and Forecast 2025-2031 (Sales Value USD Million)
10.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Anticonvulsants
10.1.2.Antidepressants
10.1.3.Antidopaminergics
10.1.4.Antipsychotics
10.1.5.Others
10.2.  Route of Administration Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Oral
10.2.2.Parenteral
10.3.  Distribution Channel Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospitals pharmacies
10.3.2.Retail pharmacies
10.3.3.Online pharmacies
10.4.  Country Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
10.4.7.
11. Asia Pacific (APAC) Huntingtons Disease Treatment Market ,2020-2024 and Forecast 2025-2031 (Sales Value USD Million)
11.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Anticonvulsants
11.1.2.Antidepressants
11.1.3.Antidopaminergics
11.1.4.Antipsychotics
11.1.5.Others
11.2.  Route of Administration Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Oral
11.2.2.Parenteral
11.3.  Distribution Channel Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospitals pharmacies
11.3.2.Retail pharmacies
11.3.3.Online pharmacies
11.4.  Country Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12. Middle East and Africa (MEA) Huntingtons Disease Treatment Market ,2020-2024 and Forecast 2025-2031 (Sales Value USD Million)
12.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Anticonvulsants
12.1.2.Antidepressants
12.1.3.Antidopaminergics
12.1.4.Antipsychotics
12.1.5.Others
12.2.  Route of Administration Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Oral
12.2.2.Parenteral
12.3.  Distribution Channel Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospitals pharmacies
12.3.2.Retail pharmacies
12.3.3.Online pharmacies
12.4.  Country Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13. Latin America Huntingtons Disease Treatment Market ,2020-2024 and Forecast 2025-2031 (Sales Value USD Million)
13.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Anticonvulsants
13.1.2.Antidepressants
13.1.3.Antidopaminergics
13.1.4.Antipsychotics
13.1.5.Others
13.2.  Route of Administration Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Oral
13.2.2.Parenteral
13.3.  Distribution Channel Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospitals pharmacies
13.3.2.Retail pharmacies
13.3.3.Online pharmacies
13.4.  Country Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Teva Pharmaceuticals Industries Ltd. (Israel)
14.2.2.Valent Pharmaceuticals International Inc. (Canada)
14.2.3.Alnylam Pharmaceuticals, Inc. (U.S.)
14.2.4.Intellect Neurosciences, Inc. (U.S.)
14.2.5.H. Lundbeck A/S (Denmark)
14.2.6.F. Hoffmann La Roche Ltd. (Switzerland)
14.2.7.QR Pharma, Inc. (U.S.)
14.2.8.Voyager Therapeutics, Inc. (U.S.)
15. Research Methodology 
16. Appendix and Abbreviations 

Key Market Players

  • Teva Pharmaceuticals Industries Ltd. (Israel)
  • Valent Pharmaceuticals International Inc. (Canada)
  • Alnylam Pharmaceuticals, Inc. (U.S.)
  • Intellect Neurosciences, Inc. (U.S.)
  • H. Lundbeck A/S (Denmark)
  • F. Hoffmann La Roche Ltd. (Switzerland)
  • QR Pharma, Inc. (U.S.)
  • Voyager Therapeutics, Inc. (U.S.)

Related Industry Reports

Oral Contraceptive Pills Market

Oral Solid Dosage Pharmaceutical Formulation Market

Global Foodborne Diseases Treatment Market

Global Psoriasis Treatment Market